European Companies Search Engine
EU funding (€8,547,712): MULti-Tumour based prediction and manipulation of Immune Response Hor1 Jan 2024 EU Research and Innovation programme "Horizon"
Text
MULti-Tumour based prediction and manipulation of Immune Response
Only few patients respond to tumor treatment as desired. Treatment heavily relies on host tumor interactions, including exploiting the host immune response against the tumor. The underlying mechanisms of host tumor interaction are largely unknown, guidance on specific intervention is missing. To improve outcome, better understanding of tumor-host interaction is needed. Large numbers of molecular snapshots will provide increased phenotyping coverage and better represent tumor-host evolution over time. In an innovative approach, MULTIR aims at investigating not a single tumor entity, but at compiling data from melanoma, lung and bladder cancer (most drugs target specific molecular features, irrespective of the tumor origin) to identify with high power the critical elements in the tumor-host interaction responsible for therapy response. In a multi-disciplinary approach involving leading clinicians, immunologists, experts in omics, digital technologies, social sciences and patient representatives from 10 EU countries and beyond, and an extensive outreach plan to ensure rapid transfer of MULTIR output to society, MULTIR combines existing multi-layer (epidemiological, genetic, clinical, pathologic, imaging, molecular) data from major studies on these tumors, using AI-based approaches to unveil functional modules regulating tumor-host interactions followed by validation of findings in models and synthetic patients. Harmonization with major EU initiatives will maximize use of European resources. Impact on all scientific, technological and societal levels is expected, including increased understanding of tumor-host interactions, generation of a unique resource of harmonized data on three major cancer types available to the community in compliance to the legal and ethics framework, boost of drug discovery, and an AI-based predictor for treatment response. MULTIR outreach plan includes policymakers and regulators, to support prompt assessment and uptake into the health systems. This action is part of the Cancer Mission cluster of projects on “Understanding (tumour-host interactions)”.
Funded Companies:
| Company name | Funding amount |
| Royal Institution FOR THE Advancement OF Learning Mcgill University | ? |
| Aarhus Universitet | €1,498,228 |
| ATOMIC INTELLIGENCE d.o.o. | €815,750 |
| Centre Hospitalier Universitaire de Nantes | €300,838 |
| Elliniki Ogkologiki Erevnitiki Omada | €687,500 |
| Eticas Data Society | €322,500 |
| Exelixis Diacheirisi Erevnas Kai Epikoinonia ΕΕ | €277,500 |
| Folkehelseinstituttet | €211,625 |
| Idryma Iatroviologikon Ereunon Akademias Athinon | €315,280 |
| Institut National de la Sante et de la Recherche Medicale | €851,535 |
| Medizinische Universitaet Wien | €254,750 |
| MOSAIQUES DIAGNOSTICS GmbH | €736,703 |
| Sorbonne Universite | €50,000 |
| STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM | €477,125 |
| UNIVERSITAETSKLINIKUM ESSEN | €807,375 |
| University College Dublin, National University of Ireland, Dublin | €941,004 |
Source: https://cordis.europa.eu/project/id/101136926
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Royal Institution FOR THE Advancement OF Learning Mcgill University, Montreal, Canada.
